GlassScriptPhysician profile
Tina M Gregg
NPI 1649463050
$20,477.04
in general payments reported to CMS, 2019-2025
27 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $760 · 2022: $837 · 2023: $1,273 · 2024: $5,481 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,640 · Food and Beverage: $4,699 · Travel and Lodging: $4,056 · Consulting Fee: $1,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,640.00 |
| Food and Beverage | $4,698.84 |
| Travel and Lodging | $4,056.03 |
| Consulting Fee | $1,485.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $15,838.85 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $936.88 | 2021-2025 | |
| Gilead Sciences, INC. | $889.14 | 2022-2024 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $883.15 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Phathom Pharmaceuticals, INC. | $251.25 | 2023-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $178.66 | 2025 | Iqirvo |
| Celgene Corporation | $169.96 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $155.90 | 2022-2025 | Ocaliva |
| Janssen Biotech, INC. | $147.81 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $135.21 | 2021-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $122.77 | 2023 | Zeposia |
| Ardelyx, INC. | $122.76 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $113.02 | 2021-2025 | Entyvio |
| Novo Nordisk INC | $93.68 | 2025 | Wegovy, Saxenda |
| Nestle Healthcare Nutrition INC. | $61.10 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $53.62 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Fujifilm Healthcare Americas Corporation | $47.03 | 2025 | |
| Lucid Diagnostics INC. | $47.00 | 2024 | |
| Ironwood Pharmaceuticals, INC | $45.37 | 2023-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $41.91 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $24.81 | 2023 | Sucraid |
| Aimmune Therapeutics, INC. | $22.01 | 2024 | |
| Orphalan INC | $21.98 | 2025 | Cuvrior |
| Genzyme Corporation | $21.54 | 2025 | |
| Evoke Pharma, INC. | $20.46 | 2023 | Gimoti |
| Daiichi Sankyo INC. | $18.35 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Gregg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.